Omnia SanaPlant Comparison
Bay-leaf willowherb vs Rosemary
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Bay-leaf willowherb and Rosemary: they share 6 indicated uses (arthritis / joint pain, cancer (anticancer research), infection (general), …); 4 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Bay-leaf willowherb | Rosemary | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 3/10 | Stronger for Rosemary |
| Cancer (anticancer research) | 2/10 | 7/10 | Stronger for Rosemary |
| Infection (general) | 1/10 | 3/10 | Stronger for Rosemary |
| Inflammation (general) | 1/10 | 8/10 | Stronger for Rosemary |
| Skin irritation | 1/10 | 3/10 | Stronger for Rosemary |
| Wounds | 1/10 | 3/10 | Stronger for Rosemary |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Characteristic Epilobium polyphenols underlying the anti-inflammatory and prostate activity; a genus review identifies oenothein B as the dominant constituent and likely driver of the antimicrobial, anti-inflammatory, anti-proliferative and antioxidant effects.
Antioxidant constituents.
Sterols associated with benign prostatic hyperplasia support.
The volatile oil, dominated by 1,8-cineole and camphor, gives the characteristic aroma and much of the antimicrobial activity.
Potent antioxidant diterpenes considered largely responsible for rosemary's strong preservative and antioxidant activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from antimicrobial action
inferred from anti-inflammatory action
Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
inferred from anti-inflammatory action
Antibacterial, including against Escherichia coli (urinary support); Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
Supports lower urinary tract symptoms of benign prostatic hyperplasia (prostate support) - a genus Epilobium review notes traditional BPH use attributed mainly to oenothein B, though clinical evidence is not yet conclusive
inferred from anti-inflammatory action
inferred from anticancer action
inferred from neuroprotective action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from antispasmodic action
inferred from antispasmodic action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Lower urinary tract / prostate symptoms must be medically assessed first to exclude prostate cancer; willowherb is a supportive measure, not a substitute for diagnosis and treatment.
Well tolerated over three months in clinical use; longer-term safety data are limited.
Culinary use is entirely safe. Essential oil should not be ingested in large amounts; avoid during pregnancy in medicinal doses. May trigger epileptic seizures in predisposed individuals at high doses. May interact with anticoagulants and antiplatelet drugs.
Duke (2002) does not appear to include a dedicated entry for rosemary (Salvia rosmarinus / Rosmarinus officinalis) as a primary herb entry in the section searched; however, rosemary is referenced throughout the text in relation to antioxidant and antimicrobial properties of its key compounds (carnosol, rosmarinic acid). Commission E (KOM) approves rosemary for dyspeptic complaints and externally for rheumatic conditions and circulatory problems.
External Ids
Botanical Description
Slender, softly hairy perennial herb with narrow, lance-shaped leaves and small, four-petalled, pale pink to lilac flowers with a notched tip, borne singly in the upper leaf axils. After flowering, long, narrow seed pods split to release cottony-tufted seeds, typical of the willowherb genus.[13]
Evergreen, woody shrub (Lamiaceae), 1-2 m tall, with dense, needle-like, dark green, aromatic leaves, white-felted beneath. Small, pale blue to violet, two-lipped flowers are borne in the leaf axils.[1]
Habitat
Grows in damp meadows, ditches, streamsides and waste ground on moist soils; native to Europe and temperate Asia.[13]
Native to the Mediterranean coast, growing on dry, rocky, sunny slopes and coastal scrub; widely cultivated as a culinary and medicinal herb worldwide, tolerating poor, well-drained soils and drought.[1]
Harvesting
The flowering aerial parts are cut in summer while in flower, and dried in a warm, shaded, airy place.[13]
Leafy sprigs are cut throughout the year (the plant is evergreen), though essential-oil content is often considered highest just before or during flowering; leaves are stripped from the stem and dried, or used fresh.[1]
Traditional Uses
Small-flowered willowherb, along with related Epilobium species, has a Central European folk tradition as a supportive remedy for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and prostatitis, and as an antimicrobial and anti-inflammatory herb for minor infections; the traditional prostate-support use is attributed mainly to its oenothein B content, though robust clinical evidence remains limited.[13]
Rosemary has an ancient Mediterranean reputation as a memory and circulation tonic ('rosemary for remembrance'), a digestive carminative, and an antiseptic for minor wounds. Commission E approves it for dyspeptic complaints internally and for rheumatic conditions and circulatory problems externally; modern research on rosmarinic acid and carnosic acid supports antioxidant, anti-inflammatory, antimicrobial and cognitive-supportive activity.[1]
Preparations
Dried flowering herb infused in hot water as a traditional urinary and prostate-support tea.
Dosage
The EU herbal monograph gives 1.5-2.0 g of the comminuted herb in 250 mL of boiling water as an infusion, twice daily, in adults and elderly; long-term use is possible. Lower urinary tract or prostate symptoms should always be medically assessed first, and the monograph directs that a doctor be consulted if fever, spasms, blood in the urine, painful urination or urinary retention occur. Educational reference only, not a prescription.
Commission E approves rosemary for dyspeptic complaints (internal use) and, externally, for rheumatic conditions and circulatory problems; typical internal use is roughly 2-4 g dried leaf as tea, up to three times daily. Educational reference only, not a prescription; avoid concentrated essential oil internally and in pregnancy/epilepsy.
References
Lookalikes Review
References & Sources
- Vitalone, A. and Allkanjari, O (2018) 'Epilobium spp: Pharmacology and Phytochemistry', Phytotherapy Research, 32(7), pp. 1229-1240. doi:10.1002/ptr.6072 Traditional / reference
https://doi.org/10.1002/ptr.6072 - Cicero, A.F.G., Allkanjari, O., Busetto, G.M., Cai, T. et al (2019) 'Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer', Archivio Italiano di Urologia e Andrologia, 91(3), pp. 139-152. doi:10.4081/aiua.2019.3.139 Traditional / reference
https://doi.org/10.4081/aiua.2019.3.139 - Vlase, A.M., Toiu, A., Gligor, O., Muntean, D. et al (2024) 'Investigation of Epilobium hirsutum L. Optimized Extract's Anti-Inflammatory and Antitumor Potential', Plants (Basel), 13(2), pp. 198. doi:10.3390/plants13020198 Preclinical
https://doi.org/10.3390/plants13020198 - Granica, S., Piwowarski, J.P., Czerwinska, M.E. and Kiss, A.K (2014) 'Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review', Journal of Ethnopharmacology, pp. 316--346. doi:10.1016/j.jep.2014.08.036 Traditional / reference
https://doi.org/10.1016/j.jep.2014.08.036 - Ramstead, A.G., Schepetkin, I.A., Quinn, M.T. and Jutila, M.A (2012) 'Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFN-gamma production by lymphocytes', PLoS One, 7(11), pp. e50546. doi:10.1371/journal.pone.0050546 Preclinical
https://doi.org/10.1371/journal.pone.0050546 - Kiss, A.K., Bazylko, A., Filipek, A., Granica, S., Jaszewska, E., Kiarszys, U., Kosmider, A. and Piwowarski, J (2011) 'Oenothein B's contribution to the anti-inflammatory and antioxidant activity of Epilobium sp', Phytomedicine, 18(7), pp. 557-560. doi:10.1016/j.phymed.2010.10.016 Preclinical
https://doi.org/10.1016/j.phymed.2010.10.016 - Schepetkin, I.A., Kirpotina, L.N., Jakiw, L., Khlebnikov, A.I., Blaskovich, C.L., Jutila, M.A. and Quinn, M.T (2009) 'Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium', Journal of Immunology, 183(10), pp. 6754-6766. doi:10.4049/jimmunol.0901827 Preclinical
https://doi.org/10.4049/jimmunol.0901827 - Ducrey, B., Marston, A., Gohring, S., Hartmann, R.W. and Hostettmann, K (1997) 'Inhibition of 5-alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species', Planta Medica, 63(2), pp. 111-114. doi:10.1055/s-2006-957624 Preclinical
https://doi.org/10.1055/s-2006-957624 - Schepetkin, I.A., Ramstead, A.G., Kirpotina, L.N., Voyich, J.M., Jutila, M.A. and Quinn, M.T (2016) 'Therapeutic potential of polyphenols from Epilobium angustifolium (fireweed)', Phytotherapy Research, 30(8), pp. 1287-1297. doi:10.1002/ptr.5648 Meta-analysis / review
https://doi.org/10.1002/ptr.5648 - Merighi, S., Travagli, A., Tedeschi, P., Marchetti, N. and Gessi, S (2021) 'Antioxidant and anti-inflammatory effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum plant extracts in macrophage and microglial cells', Cells, 10(10), pp. 2691. doi:10.3390/cells10102691 Preclinical
https://doi.org/10.3390/cells10102691 - Hevesi Toth, B., Blazics, B. and Kery, A (2009) 'Polyphenol composition and antioxidant capacity of Epilobium species', Journal of Pharmaceutical and Biomedical Analysis, 49(1), pp. 26-31. doi:10.1016/j.jpba.2008.09.047 Preclinical
https://doi.org/10.1016/j.jpba.2008.09.047 - Vitalone, A., McColl, J., Thome, D., Costa, L.G. and Tita, B (2003) 'Characterization of the effect of Epilobium extracts on human cell proliferation', Pharmacology, 69(2), pp. 79-87. doi:10.1159/000072360 Preclinical
https://doi.org/10.1159/000072360 - Steenkamp, V., Gouws, M.C., Gulumian, M., Elgorashi, E.E. and van Staden, J (2005) 'Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis', Journal of Ethnopharmacology, pp. 2005. doi:10.1016/j.jep.2005.07.007 Traditional / reference
https://doi.org/10.1016/j.jep.2005.07.007 - European Medicines Agency (HMPC) (2015) 'European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l-andor-epilobium-parviflorum-schreb-herba_en.pdf - Coulson, S., Rao, A., Beck, S.L., Steels, E., Gramotnev, H. and Vitetta, L (2013) 'A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation (containing Epilobium parviflorum) for the management of symptoms of benign prostatic hypertrophy', Complementary Therapies in Medicine. doi:10.1016/j.ctim.2013.01.007 Randomized trial
https://doi.org/10.1016/j.ctim.2013.01.007
- de Oliveira, J.R., Camargo, S.E.A. and de Oliveira, L.D (2019) 'Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent', Journal of Biomedical Science, 26(1), pp. 5. doi:10.1186/s12929-019-0499-8 Meta-analysis / review
https://doi.org/10.1186/s12929-019-0499-8 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2025) 'Toxicity and safety of rosemary (Rosmarinus officinalis): a comprehensive review', Naunyn-Schmiedeberg's Archives of Pharmacology, 398(1), pp. 9-23. doi:10.1007/s00210-024-03336-9 Meta-analysis / review
https://doi.org/10.1007/s00210-024-03336-9 - Zhang, L. and Lu, J (2024) 'Rosemary (Rosmarinus officinalis L.) polyphenols and inflammatory bowel diseases: Major phytochemicals, functional properties, and health effects', Fitoterapia, 177, pp. 106074. doi:10.1016/j.fitote.2024.106074 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2024.106074 - Ahmed, H.M. and Babakir-Mina, M (2020) 'Investigation of rosemary herbal extracts (Rosmarinus officinalis) and their potential effects on immunity', Phytotherapy Research, 34(8), pp. 1829-1837. doi:10.1002/ptr.6648 Preclinical
https://doi.org/10.1002/ptr.6648 - Li, T., Wang, W., Guo, Q., Li, J. and others (2023) 'Rosemary (Rosmarinus officinalis L.) hydrosol based on serotonergic synapse for insomnia', Journal of Ethnopharmacology, 318(Pt B), pp. 116984. doi:10.1016/j.jep.2023.116984 Preclinical
https://doi.org/10.1016/j.jep.2023.116984 - Hassani, F.V., Shirani, K. and Hosseinzadeh, H (2016) 'Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review', Naunyn-Schmiedeberg's Archives of Pharmacology, 389(9), pp. 931-949. doi:10.1007/s00210-016-1256-0 Meta-analysis / review
https://doi.org/10.1007/s00210-016-1256-0 - Gonzalez-Vallinas, M., Reglero, G. and Ramirez de Molina, A (2015) 'Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy', Nutrition and Cancer, 67(8), pp. 1221-1229. doi:10.1080/01635581.2015.1082110 Meta-analysis / review
https://doi.org/10.1080/01635581.2015.1082110 - Hussain, S.M., Syeda, A.F., Alshammari, M., Alnasser, S. and others (2022) 'Cognition enhancing effect of rosemary (Rosmarinus officinalis L.) in lab animal studies: a systematic review and meta-analysis', Brazilian Journal of Medical and Biological Research, 55, pp. e11593. doi:10.1590/1414-431X2021e11593 Meta-analysis / review
https://doi.org/10.1590/1414-431X2021e11593 - Nematolahi, P., Mehrabani, M., Karami-Mohajeri, S. and Dabaghzadeh, F (2018) 'Effects of Rosmarinus officinalis L. on memory performance, anxiety, depression, and sleep quality in university students: A randomized clinical trial', Complementary Therapies in Clinical Practice, 30, pp. 24-28. doi:10.1016/j.ctcp.2017.11.004 Randomized trial
https://doi.org/10.1016/j.ctcp.2017.11.004 - Ulbricht, C., Abrams, T.R., Brigham, A., Ceurvels, J. and others (2010) 'An evidence-based systematic review of rosemary (Rosmarinus officinalis) by the Natural Standard Research Collaboration', Journal of Dietary Supplements, 7(4), pp. 351-413. doi:10.3109/19390211.2010.525049 Meta-analysis / review
https://doi.org/10.3109/19390211.2010.525049 - Hoffmann, D (2003) 'Medical Herbalism'. Traditional / reference
https://scholar.google.com/scholar?q=Medical%20Herbalism - Moss, M., Cook, J., Wesnes, K. and Duckett, P (2003) 'Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults', 113(1), pp. 15--38. doi:10.1080/00207450390161903 Clinical study
https://doi.org/10.1080/00207450390161903 - Petersen, M. and Simmonds, M.S.J (2003) 'Rosmarinic acid', 62(2), pp. 121--125. Traditional / reference
https://scholar.google.com/scholar?q=Rosmarinic%20acid - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.